ABBV Jun 2024 175.000 put
| Previous close | 34.05 |
| Open | 34.05 |
| Bid | 26.15 |
| Ask | 27.15 |
| Strike | 175.00 |
| Expiry date | 2024-06-21 |
| Day's range | 34.05 - 34.05 |
| Contract range | N/A |
| Volume | |
| Open interest | 5 |
Motley FoolLooking for Dividend Growth in the New Year? 3 Magnificent Stocks to Buy Now.
For that reason, as you prepare your portfolio for the next investing year, it's a great idea to add a few dividend stocks to the mix. Which dividend stocks should you select? Plus, the sooner you get in on these players, the sooner you can start collecting dividends.
- Reuters
PRESS DIGEST- Wall Street Journal - Dec. 7
The following are the top stories in the Wall Street Journal. - Meta Platforms said it has started fully encrypting messages on Facebook by default, and will automatically start shifting Facebook users to so-called end-to-end encryption for their messages on that platform and its connected Messenger app. - BHP Group has appointed Vandita Pant as its new chief financial officer, as part of a reshuffle of its top executives from March 2024.
ReutersCerevel options trading surge before AbbVie deal news raises eyebrows
Trading in the options of Cerevel Therapeutics Holdings Inc experienced an unusual surge along with its stock price in the days before Wednesday's announcement that AbbVie would buy the drug developer in a multi-billion dollar deal. AbbVie said after the market close on Wednesday it would buy Cerevel for about $8.7 billion in a bid to replace revenue as its huge-selling arthritis drug Humira faces a raft of new competitors. AbbVie's offer was priced at $45 a share.
